Orthocell has released interim results from a real-world evidence (RWE) study evaluating its collagen nerve repair product, Remplir™, reporting an overall treatment success rate of 81.1% following nerve repair procedures.
Key findings from the study include:
- 81.2% of muscles innervated by repaired nerves achieved functional motor recovery.
- 89.5% of nerve decompression procedures resulted in significant improvement or complete relief of symptoms.
- No post-treatment complications or adverse reactions to Remplir were reported in any patient.
- Results were consistent with previously published clinical trial outcomes.
According to Orthocell, these results support the reliability of Remplir outcomes. The company notes that over 200 surgeons across more than 165 hospitals are currently using the product.
Orthocell states that this new data will support its ongoing medical education initiatives during the US sales rollout, and will also provide evidence for its regulatory submission in the European Union and United Kingdom, expected in the fourth quarter of calendar year 2025.
Orthocell CEO and MD, Paul Anderson, said:
“We are delighted with the interim results from our Remplir RWE Study, validating the superior Remplir clinical outcomes, previously published in a highly regarded, peer reviewed journal. This performance is why more than 200 surgeons across more than 165 hospitals are now using Remplir and these numbers continue to grow.
It is imperative that we continue to collect performance data to drive the rapid market adoption in the US and support the EU & UK regulatory applications.”
Want to keep up on regenerative medicine? Get the weekly newsletter here.
